Pill Identifier App

Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases

Clinical results and advantage over linezolid in resistance acquisition by Staph aureus among data to be presented at infectious disease meeting

SAN DIEGO, Calif., May 6 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing best-in-class drugs for the treatment of serious bacterial infections, announced today that the results of multiple studies from its lead program, torezolid (TR-701), will be presented in an oral session and six poster presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in Helsinki, Finland May 16-19. Torezolid is a novel antibiotic that recently completed Phase 2 clinical development with potent activity against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

  The presentations are as follows:

  Saturday, May 16th

  Oral Presentation  - Lecture Hall 3a (14:54 - 15:06)

  --  O28: In vivo pharmacodynamics of TR-701, a new oxazolidinone
      antibiotic, against methicillin-susceptible and methicillin-resistant
      Staphylococcus aureus strains; A. Louie, C. Fregeau, W. Liu, H. Conde,
      R. Kulawy, G. Drusano

  Sunday, May 17th

Poster Presentations - New antimicrobials against Gram-positives (13:30 - 14:30)

  --  P 1091: Effects of food on the pharmacokinetics of TR-701, a novel
      oxazolidinone prodrug antibiotic, in healthy adult subjects; KA.
      Munoz, P. Bien, P. Prokocimer, M. Berry, C. R. Bethune
  --  P 1092: TR-700, a novel methyltetrazolyl-oxazolidinone, accumulates
      extensively within human macrophages cells and shows activity towards
      intraphagocytic linezolid-sensitive and linezolid-resistant S. aureus;
      S. Lemaire, K. Kosowska-Shick, P. Appelbaum, F. Van Bambeke, P.
      Tulkens
  --  P 1090: The safety of single ascending oral doses of TR-701, a novel
      oxazolidinone prodrug antibiotic; P. Bien, P. Prokocimer, KA. Munoz,
      J. Bohn
  --  P 1089: The safety of multiple ascending oral doses of TR-701, a novel
      oxazolidinone prodrug antibiotic; P. Bien, P. Prokocimer, KA. Munoz,
      J. Bohn
  --  P 1103: Characterization of resistance following serial passage of
      Staphylococcus aureus in the presence of the novel oxazolidinone
      TR-700 and linezolid; J. Locke, K. Shaw

  --  P 1104: Characterization of the novel oxazolidinone TR-700 and
      linezolid spontaneous mutation frequencies and resistance mechanisms
      in Staphylococcus aureus; J. Locke, K. Shaw

Copies of these posters will be available on the Trius Web site following the ECCMID meeting: http://www.triusrx.com/posters.php.

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R), the only marketed antibacterial drug of the oxazolidinone class. Trius has recently completed Phase 2 testing of torezolid in a U.S. based multi-center trial. Trius' pipeline includes two preclinical programs with lead candidates being developed to treat serious infections caused by Gram-negative bacterial pathogens. For more information, visit www.triusrx.com.

Source: Trius Therapeutics, Inc.

CONTACT: Jason Spark of Porter Novelli Life Sciences, +1-619-849-6005,
jspark@pnlifesciences.com, for Trius Therapeutics, Inc.

Web Site: http://www.triusrx.com/
 

Posted: May 2009

View comments

Hide
(web5)